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Among the gynecological malignancies, ovarian cancer is the most fatal due to its
high mortality rate. Most of the identified cases are epithelial ovarian cancer (EOC)
with five distinct subtypes: high-grade serous carcinoma, low-grade serous carcinoma,
mucinous carcinoma, endometrioid carcinoma, and clear-cell carcinoma. Lack of an
early diagnostic approach, high incidence of tumor relapse and the heterogenous
characteristics between each EOC subtypes contribute to the difficulties in developing
precise intervention and therapy for the patients. MicroRNAs (miRNAs) are single-
stranded RNAs that have been shown to function as tumor suppressors or oncomiRs.
The miR-200 family, especially miR-200c, has been shown to be implicated in the
metastasis and invasion of ovarian carcinoma due to its functional regulation of epithelial-
to-mesenchymal transition (EMT). This mini review is aimed to summarize the recent
findings of the miR-200c functional role as well as its validated targets in the metastasis
cascade of ovarian cancer, with a focus on EMT regulation. The potential of this miRNA
in early diagnosis and its dual expression status are also discussed.
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INTRODUCTION
Ovarian cancer has the highest prevalence among the gynecological cancers worldwide with more
than 238, 700 newly diagnosed cases and 151, 900 reported deaths per year (Ferlay et al., 2015;
Siegel et al., 2016). Among the ovarian malignancies, 90% of the cases are epithelial ovarian cancer
(EOC) with five identified subtypes namely, high-grade serous carcinoma (70%), low-grade serous
carcinoma (<5%), mucinous carcinoma (3%), endometrioid carcinoma (10%), and clear-cell
carcinoma (10%) (Prat, 2012b). The majority of these EOC categories are heterogeneous in nature,
with distinct epidemiological and genetic factors, molecular profiles and behavioral responses
toward chemotherapy and other treatments (Prat, 2012a; Groen et al., 2015), contributing to the
difficulties in designing effective therapeutic strategies. Also, the lack of an early screening strategy
(Buys et al., 2011) and the rather high rate of tumor relapse (Mei et al., 2013) increase the mortality
rates in ovarian cancer patients. Therefore, it is necessary to develop more precise and effective
treatment strategies in order to improve the survival rates for women diagnosed with this cancer.
MicroRNAs (miRNAs) have been recognized as a class of molecular regulators and potential
therapeutic agents in cancers. miRNAs are short single-stranded non-coding RNAs (∼21
nucleotides in length) which are able to negatively regulate gene expression by binding to
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complementary sites in the target messenger RNA (mRNA) at
the 3′ untranslated regions (Fabian et al., 2010). Biosynthesis
of miRNAs starts with the transcription of miRNAs in the
nuclei (Lee et al., 2002; reviewed, Beezhold et al., 2010) and
followed by the cleavage of miRNAs by Drosha complex into
a distinctive stem-loop structure (Lee et al., 2003; reviewed,
Beezhold et al., 2010). These miRNAs are exported to the
cytoplasm, in which RNAse III enzyme, Dicer, cuts the miRNAs
into single-stranded miRNAs (Ketting et al., 2001; reviewed,
Beezhold et al., 2010). One strand of the miRNAs is integrated
into Argonaute 2 protein complex to produce the RNA-induced
silencing complex. A perfect complementary binding between
miRNA and its mRNA target will lead to mRNA degradation,
while ‘incomplete matching’ binding will lead to translational
repression of the mRNA (Di Leva et al., 2006; Beezhold et al.,
2010). Since one miRNA can target many genes (Royo et al.,
2006), the evidence of miRNAs forming coordinated regulatory
networks (Fazi and Nervi, 2008; Chowdhury et al., 2014) and act
as oncomiRs or tumor suppressors may provide a novel function
of these miRNAs as biomarkers for diagnosis or therapeutic
purposes.
Several miRNAs have been shown to be implicated in ovarian
cancers and one of them is the miR-200 family, which is
abundantly expressed by epithelial tissues (Pal et al., 2015).
The miR-200 family derives from two miR gene clusters; miR-
200a, miR-200b, and miR-429 that are located at chromosome
1p33.36, and miR-200c and miR-141 that are located at
chromosome 12p13.31 (Table 1) (Muralidhar and Barbolina,
2015). These miRNAs share a high degree of sequence homology
(Table 1) with only one nucleotide difference at their seed
sequence (Muralidhar and Barbolina, 2015), and they are usually
categorized functionally by their seed sequence due to possible
same target genes (Pecot et al., 2013). The Cancer Genome
Atlas (TCGA) group performed genome analysis of 408 high-
grade serous EOC (HGSOC) to identify molecular regulatory
networks involved in EOC (The Cancer Genome Atlas Research
Network, 2011). In this study (The Cancer Genome Atlas
Research Network, 2011), they found that 89% of the affected
genes were predicted to be regulated by eight main miRNAs
including two members of miR-200 families which were miR-
141 and miR-200a. Chen et al. (2013) systematically reviewed
studies on miRNAs profiling of EOC and validated the findings
from eight studies. They concluded that miR-141, miR-200a,
miR-200b, and miR-200c were consistently upregulated only in
four of the reported studies (Chen et al., 2013). One reason
mentioned for such inconsistencies is that previous miRNAs
profiling studies used various types of controls, and only a few
did the comparison to normal ovarian epithelial cells, which is
the most appropriate control (Zorn et al., 2003). A recent study
performed on a larger EOC cohort (n = 100) and using ovarian
epithelial cells as controls, confirmed that similar upregulation
of these miRNAs was observed in EOC samples (Cao et al.,
2014). Importantly, elevated expression of miR-200a and miR-
200b was associated with advanced and high-grade tumors, while
high miR-200c expression was only associated with advanced
tumors (23). These diverse expression profiles of miR-200 family
in different EOC progression and subtypes may suggest that
miR-200’s regulatory role depends on the stage and histology
profile of the ovarian cancer. Recent publications on the functions
of miR-200 in ovarian cancer revealed that members of miR-
200 family mainly act as metastases inhibitors (Iorio et al.,
2007; Hu et al., 2009; Díaz-López et al., 2014; Kinose et al.,
2014; Humphries and Yang, 2015; Muralidhar and Barbolina,
2015; Pal et al., 2015), however, there is still no differentiation
of the roles of the individual members of the miR-200 family
and how each of them regulate cancer progression especially in
terms of ovarian cancer pathogenesis. Moreover, within the miR-
200 family, miR-200c has also been shown to be a marker for
epithelial-mesenchymal transition (EMT), which is the important
step of cancer metastasis (Iorio et al., 2007; Hu et al., 2009; Díaz-
López et al., 2014; Kinose et al., 2014; Humphries and Yang,
2015; Muralidhar and Barbolina, 2015; Pal et al., 2015). Therefore,
this mini review will summarize the current knowledge on
the downstream targets of miR-200 in ovarian cancer with an
emphasis on the functional role of miR-200c in the metastasis
cascade and discuss the prospective value and issues in early
screening strategy for ovarian cancer.
miR-200c-MEDIATED METASTASIS
Metastasis is defined as the multi-step processes of cancer cells
colonization of distant organ or tissues (secondary/metastatic
tumors) from the primary tumor site (Wan et al., 2013). Six main
steps are involved namely: (1) tumor growth and angiogenesis
at the primary site, (2) stromal invasion and detachment from
extracellular matrix (ECM), (3) intravasation into the circulation,
(4) survival in the circulation, (5) extravasation at secondary site,
and (6) colonization of the new secondary site (Wan et al., 2013;
Humphries and Yang, 2015). A recent review highlighted the
role of the miR-200 family in each of the six steps (Humphries
and Yang, 2015). Figure 1 shows the summary of the actions of
miR-200c action and its validated targets in each step discussed
below.
Metastasis Routes of the Ovarian Cancer
Progression
Differently to other tumors, majority of EOC metastasize to
adjacent sites along the peritoneum throughout the pelvic and
abdominal cavity. The most common identified metastatic sites
are including the pelvic wall, omentum and mesentery, though
there are other adjacent metastatic sites have also been reported
such as skin and lymph nodes (Cheng et al., 2009). Ovarian
tumor cells spread through the peritoneal fluid or known as
transcoelomic route of metastasis from the pelvic up to intestinal
mesentery that allows for implantation of the tumors to different
peritoneal organs (Meyers et al., 1987; Coakley and Hricak,
1999; Carmignani et al., 2003; Nougaret et al., 2012; Le, 2013).
Though, this implantation of tumors depends on the fluidity of
the peritoneum in which less fluidity will restrict the movement
of the tumor cells at the primary site (Carmignani et al., 2003;
Tan et al., 2006; Feki et al., 2009), thus may results in the
accumulation of ascites in the abdomen. The formation of
ascites is not well understood, yet previous studies have shown
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TABLE 1 | miR-200 members’ functional groups and seed sequences.
miR-200 Chromosome location Mature seed sequence (5′–3′) Functional group
miR-200a 1p33.36 UAA C ACUGUCUGGUAACGAUGU Group I
miR-200b 1p33.36 UAA U ACUGCCUGGUAAUGAUGA Group II
miR-429 1p33.36 UAA U ACUGUCUGGUAAAACCGU Group II
miR-200c 12p13.31 UAA U ACUGCCGGGUAAUGAUGGA Group II
miR-141 12p13.31 UAA C ACUGUCUGGUAAAGAUGG Group I
miR-200 family arises from two different gene clusters which are the chromosome 1p33.36 (miR-200a/b/429) and chromosome 12p13.31 (miR-200c/141). These miRNAs
shares similar seed sequences (2–8 nucleotides) with a difference at 4th position (highlighted).
FIGURE 1 | Functional regulation of metastasis cascade by miR-200c and its validated targets. Illustration of miR-200c functional role and its validated
target in each of the metastases cascade. ECM, extracellular matrix.
that ascites accumulation is regulated by VEGF (Kraft et al.,
1999; Xu et al., 2000), a validated target of miR-200c, and
ascetic fluid is primarily composed of tumor cells, white blood
cells and lactate dehydrogenase (Runyon et al., 1988; Bansal
et al., 1998; Feki et al., 2009; Kalogeraki et al., 2012). These
floating tumor cells in ascites usually in multicellular spheroids
(Lengyel, 2010) and implantation of these spheroids involves
involves interactions between mesothelium and tumor cells
within peritoneal cavity, thus may also interacting the adjacent
areas including peritoneum, bowel, omentum and serosa (Daya
and Elliott McCaughey, 1991; Kenny et al., 2007).
In rare occurrence, much further metastatic sites of the
ovarian carcinoma have also been reported such as in the
brain (Koul et al., 2001; Sekine et al., 2013; Longo et al.,
2014), breast (Dursun et al., 2009; Karam et al., 2009; Abbas
et al., 2013; Tempfer et al., 2016), lung (Carbonari et al., 2015;
Upadhyay et al., 2015), pancreas (Nakamura et al., 2016), and
gastrointestinal track (Zhou and Miao, 2012), thus suggesting
an alternative route of metastasis in EOC. Previous studies have
reported that the presence of circulating tumor cells (CTCs) in
the blood circulation of the ovarian cancer patients (Pecot et al.,
2011; Phillips et al., 2012), which implies that ovarian tumor
cells may also follow ‘hematogenous’ route of metastasis through
blood stream. In fact, Pradeep et al. (2014) showed that ovarian
CTCs prefers hematogenous metastasis in a parabiosis animal
model. In this study (Pradeep et al., 2014), the female mice had
their skin removed from shoulder to the hip joint and then
pairs of these female mice were surgically anastomosed. In each
mice pairs, ovarian carcinoma cells (SKOV3ip1) were injected
to abdominal cavity in one of the mice and these tumor cells
metastasized to the omentum of the other mice (Pradeep et al.,
2014). The immunofluorescent staining showed that both of the
paired mice shared blood not lymphatic vessels (Pradeep et al.,
2014) thus confirms the hematogenous route of circulation. This
preferential hematogenous metastasis route is depends on the
ERBB3/NGR1 signaling axis, whereby the suppression any of
these molecular regulators, led to substantial reduction of the
tumor metastasis (Pradeep et al., 2014). ERBB3, ERB-B2 tyrosine
kinase 3 protein is a member of epidermal growth factor receptor
(EGFR) family in which it binds to other kinases in EGFR
family such as Neuregulin1, NGR1 and activates downstream
signaling for cell proliferation and differentiation (Zhang K. et al.,
2013; Reif et al., 2016). Moreover, recent study in mice also
showed that ovarian tumor cells can hematogenously metastasize
with the preference to the ovary (Coffman et al., 2016). This
particular study (Coffman et al., 2016) is vital due to there are
emerging findings that suggest that HGSOC originates from
distant fallopian tube lesions and the progression of metastasis
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is to the ovary (Kuhn et al., 2010; Perets et al., 2013; Perets and
Drapkin, 2016), thus may suggest the hematogenous metastasis
may be the key for interventions in HGSOC. Nevertheless, there
are about 40% of ovarian cancer patients did not have fallopian
tube lesions and animal studies also showed that epithelial
ovarian cells may also be the origins for HGSOC (Flesken-Nikitin
et al., 2013; Zeppernick et al., 2015). Therefore, more works
are needed to clarify the pattern for ovarian cancer metastasis
via hematogenous route, and how it contributes to disease
progression as well as patients’ survival outcomes.
miR-200c-Mediated Tumor Growth and
Angiogenesis
There is currently limited evidence to show the suppression
of early tumor formation and growth by the miR-200 family,
and much less for miR-200c. Two studies on miR-200b showed
that the overexpression of miR-200b reduced tumor growth in
prostate (Williams et al., 2013) and breast (Humphries et al.,
2014) cancers. In contrast, another study reported that miR-200b
did not exhibit any effect on the growth of breast cancer (Li X.
et al., 2014). Since miR-200c has an identical seed region with
miR-200b, miR-200c may have a similar regulatory function in
tumor growth in the early step of metastasis. However, more
investigations are needed to verify the functional roles of the
miR-200 family, especially in ovarian cancer progression.
Early tumor development requires activation of angiogenesis
which is the establishment of new blood vessels. A previous
study on Ishikawa cells (endometrial adenocarcinoma) revealed
that restoration of miR-200c expression resulted in reduced
mRNA expression and protein level of vascular-endothelial-
growth factor (VEGF) but only the protein level of FLT1 (VEGF
receptor 1; Panda et al., 2012). Both of these factors are important
for angiogenesis. This suppression was attributed to the direct
binding of miR-200c to the VEGF mRNA 3′UTR region but not
with FLT1 mRNA (Panda et al., 2012). A similar finding was also
observed in lung cancer (Shi et al., 2013) in which miR-200c
directly targeted KDR (VEGF receptor 2). These findings were
also confirmed by a recent study in placenta tissues that showed
miR-200c negatively regulated VEGF mRNA and protein levels
(Hu et al., 2016), thus suggesting the regulation of angiogenesis
by miR-200c. In a recent study on bone cancer, overexpression
of miR-200c transformed the metastatic fast-growing tumor into
a dormant tumor both in vivo and ex vivo and prolonged the
survival rate of the mice injected with the tumors, due to the
suppression of angiogenesis (Tiram et al., 2016). This further
suggests that miR-200c negatively regulates angiogenesis and
may provide beneficial outcomes in improving patient survival.
In terms of ovarian cancer, overexpression of miR-200c in an
ovarian cancer cell line (Hey8A) decreased IL8 and CXCL1
expressions and this suppression was reversed by the presence of
miR-200c inhibitors (Pecot et al., 2013). IL8 and CXCL1 are also
critical players of tumor vasculature and angiogenesis (Merritt
et al., 2008; Tran et al., 2012; Pecot et al., 2013). Nevertheless,
recent findings showed that miR-200b is a more prominent player
in the regulation of angiogenesis compared to miR200c (Chan
et al., 2011; Choi et al., 2011; Chang et al., 2013; Pecot et al., 2013),
implying the specificity of these miRNAs despite having the
same seed sequence. Therefore, more precise and larger studies
are needed to differentiate their biological action and functional
targets in regulating angiogenesis especially in ovarian cancer
plus the implication on survival outcomes.
miR-200c-Mediated Local Invasion and
Detachment
Tumor invasion and migration involve the breaking of ECM
and invasion to stromal tissues from primary tumor site before
moving to the circulation. A study on the breast cancer
cell line, MB-231, showed that miR-200c mimics reduced
expression of formin homology domain-containing protein
1 (FHOD1) and Mg2+/Mn2+-dependent protein phosphatase
1F (PPM1F), in conjunction with reduced invasive capacities
of these MB-231 cells (Jurmeister et al., 2012). FHOD1 is
an actin-nucleating formin that is primarily involved in the
cytoskeletal rearrangement and is upregulated during EMT
transition (Gardberg et al., 2013) while PPM1F kinase is involved
in MAP kinase regulation of focal adhesion (Zhang S. et al.,
2013). In lung cancer, miR-200c inhibits cancer cell invasion
through the ubiquitin specific peptidase 25 (USP25) protein
(Li J. et al., 2014), which is a peptidase primarily associated
with protein ubiquitination and may intervene with TGFβ
signaling and EMT (Soond and Chantry, 2011). A recent study
on breast cancer to identify the functional targets of miR-200c
revealed that among 12 validated targets, CRTAP was shown
to be strongly implicated in cell invasion (Perdigao-Henriques
et al., 2016). CRTAP is a cartilage-associated protein that is
involved in the alteration of proline amino acid (proline 3-
hydroxylation) during collagen formation (Hudson and Eyre,
2013). In the case of osteogenesis imperfecta, CRTAP expression
is reduced in conjunction with the decrease in collagen binding
of a proteoglycan, Decorin, that regulates TGFβ signaling in
ECM (Grafe et al., 2014). Thus, tumor cells with decreased
collagen binding properties may gain invasive properties due to
changes in ECM properties and it will be useful to investigate
the role of CRTAP in promoting invasion and metastases
through TGFβ signaling in ovarian cancer. In another study
on breast cancer, novel validated targets of miR-200c, SH3
and PX domains 2A (TKS5), and myosin light chain kinase
(MYLK) were downregulated by miR-200c through the ZEB1
pathway (Sundararajan et al., 2015). TKS5 is involved in the
polymerization of cytoskeleton actin and ECM degradation
(Murphy and Courtneidge, 2011), while MYLK is mainly
involved in cytoskeletal rearrangement and muscle contraction
(Dudek et al., 2002; Takashima, 2009), thus consistent with the
reduced invasion and metastasis observed when these factors
were suppressed by miR-200c (Sundararajan et al., 2015). A study
on two ovarian cancer cell lines (OVCAR3 and SKOV3; Sun et al.,
2014) showed that an overexpression of miR-200c decreased
the expression and protein level of matrix metalloproteinase 3
(MMP3), which is the proteinase responsible to facilitate ECM
breakdown, thus this led to inhibition of ovarian cancer cell
invasiveness via ZEB1/pSMAD pathway, which further suggests
the role of miR-200c in the molecular pathway of ovarian
Frontiers in Pharmacology | www.frontiersin.org 4 August 2016 | Volume 7 | Article 271
fphar-07-00271 August 20, 2016 Time: 14:30 # 5
Sulaiman et al. miR-200c as Metastasis Regulator in Ovarian Cancer
cancer invasion. Another validated target of miR-200c is DLC1
(deleted in liver cancer-1), which is a tumor and metastasis
suppressor that regulates actin formation and focal adhesion
(Feng et al., 2013). In a study on EOC, forced expression of miR-
200c reduced DLC1 expression in conjunction with increased
cell proliferation and suppression of serous EOC invasion and
migration (Ibrahim et al., 2015), consistent with the known role
of DLC1.
miR-200c-Mediated
Epithelial-Mesenchymal Transition (EMT)
Gain of cell motility is one of the vital steps in tumor migration
and metastasis. One of the best described pathways (Pal et al.,
2015) is the EMT which is the first indication of the cancer
development. This EMT transition is categorized by a series of
reversible processes of molecular and phenotypic alterations in
the cells which leads to differentiation of EMT or mesenchymal
to epithelial cells (MET). The epithelial tumor cells favor EMT
to gain migration and invasive characteristics, however, when
they reach a new secondary site, MET is activated to form macro
metastasis (Craene and Berx, 2013; Nieto, 2013). This aberrant
stimulation of multiple EMT/MET cycles and its flexibility
contribute to the development of fibrosis and cancer metastases.
Usually, this EMT/MET is marked by the loss of epithelial-
cadherin protein, a type-I transmembrane protein (CDH1) which
is an identity marker of epithelial cells (Yang and Weinberg,
2008).
Two key molecular targets in miRNA-mediated EMT pathway
are the receptor-regulated SMADs (SMAD2 and SMAD3) and
ZEB family proteins (ZEB1 and ZEB2). SMAD2 and SMAD3
proteins are the downstream effectors of TGFβ signaling
pathway, whereby the activation of the TGFβ receptor leads to
phosphorylation of SMAD2 and SMAD3 (Brown et al., 2007).
Activated SMAD2 and SMAD3 will bind to SMAD4 and induce
translocation to the nucleus, in which they will interact with
different nuclear regulators and modulate transcription of target
genes (Brown et al., 2007). ZEB1 and ZEB2 are the transcriptional
repressors of CDH1 gene (Gregory et al., 2008; Park et al., 2008;
reviewed, Hill et al., 2013) and both contain two highly conserved
zinc-finger domains (Muralidhar and Barbolina, 2015). This
zinc-finger domain would allow DNA to be attached to the
E-boxes in the promoter sections of a target gene (Muralidhar
and Barbolina, 2015). Transcriptional suppression of CDH1 gene
is mediated by the binding of ZEB factors to the promoter of
CDH1 gene (Eger et al., 2005; Aigner et al., 2007). This loss of
CDH1 expression due to ZEB binding will result in migratory and
invasive properties in cells with the appearance of spindle-shaped
morphology (Vergara et al., 2010).
Hurteau et al. (2006) performed the repression of miR-200c
expression using anti-miRs oligonucleotides in various cell lines
and found that miR-200c expression was inversely correlated to
the expression of ZEB1 (Hurteau et al., 2006). A study on EMT
transition by TGFβ in MDCK cells showed that expression of
miR-200 members including miR-200c and CDH1 were reduced,
whereas ZEB1 and ZEB2 expression were elevated (Gregory
et al., 2008). This functional relationship between ZEB1 and
miR-200c was further analyzed using a ZEB1 knockdown in
breast and colorectal cancer cell lines (Burk et al., 2008). In this
study (Burk et al., 2008), a reduced ZEB1 level led to significant
overexpression of miR-200c and miR-141, and this was due to
direct binding of ZEB1 to their promoter regions (Burk et al.,
2008). The elevated miR-200c expression led to MET transition in
undifferentiated cancer cells with increased expression of CDH1.
Since then, various studies have demonstrated that miR-200c and
the ZEB family of transcription factors play major roles in the
regulation of EMT and MET (Brabletz and Brabletz, 2010; Panda
et al., 2012; Hill et al., 2013; Hur et al., 2013; Díaz-López et al.,
2014; Koutsaki et al., 2014; Sundararajan et al., 2015; Jiao et al.,
2016; Perdigao-Henriques et al., 2016).
Despite the translational suppression of ZEB by the miR-200
family, ZEB transcription factors can also regulate miR-200 gene
expression by directly binding to the miR-200 promoter and
suppress the expression (Hill et al., 2013). This negative double-
feedback regulation between miR-200 and ZEB families provides
greater flexibility in the regulation of cell fate. Normal epithelial
cells express CDH1 due to suppression of ZEB1/ZEB2 due to
high expression of miR-200 family, but changes in environment
and signals can independently stimulate ZEB1/ZEB2 expression
which causes miR-200 family and CDH1 expression to be
repressed and allowing EMT to occur (Hill et al., 2013). Both
of these ZEB regulators are implicated in miR-200-mediated
repression of CDH1 expression in epithelial cells (Gregory et al.,
2008; Park et al., 2008; Ahn et al., 2012; Hill et al., 2013; Pal
et al., 2015; Yang et al., 2015). Although miR-200c is known to
repress ZEB1/ZEB2 to restore CDH1 expression in majority of
the studies, there are reported findings that in some cancer cell
lines, restoration of CDH1 expression is due to miR-200c gain
of expression but the migration and invasiveness properties in
those cell lines were still reduced (Cochrane et al., 2010; Pacurari
et al., 2013). These findings may imply that miR-200c regulation
of cell motility is independent of CDH1 and may also suggest
miR-200c targets other molecular regulators and mechanisms
besides ZEB1/CDH1 pathway. Moreover, the absence of CDH1
gene expression in cancer can also imply that repression of CDH1
in cancer may be caused by other mechanisms such as C/A
single nucleotide polymorphism at the promoter of CDH1 (Li
et al., 2000; Wang et al., 2012) or due to CDH1 promoter hyper
methylation (Caldeira et al., 2006; Shargh et al., 2014), in which
both can suppress CDH1 expression.
Although substantial evidences show that miR-200c
importantly regulates EMT/MET in ovarian cancer progression,
lack of evidences on the transitions between epithelial to
mesenchymal tumor cells especially in morphological features
of mesenchymal-like cells in patients’ samples (Tarin, 2005;
Ledford, 2011; Tsai and Yang, 2013) lead to dispute whether
the transition between EMT to MET exists in the cancer
progression and metastasis. An integrated genomic analysis
of HGSOC done by TCGA network revealed that within
the HGSOC, there are four mRNA transcriptional subtypes,
including immunoreactive, differentiated, proliferative and
mesenchymal, and three miRNA expressional subtypes that
are overlapped with those four mRNA transcriptional subtypes
(The Cancer Genome Atlas Research Network, 2011). Although,
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TCGA analyses did not show any difference of the survival
time in the patients between those HGSOC molecular subtypes,
another study have confirmed the presence of those HGSOC
molecular subtypes and improved these molecular classifications
with prognostic values (Konecny et al., 2014). In this study
(Konecny et al., 2014), the immunoreactive subtypes HGSOC
was identified with the best survival outcomes in the patients,
while the mesenchymal and proliferative subtypes have the
worst. Nevertheless, both of these studies showed that there can
be more than one subtype in an individual at a time depending
on the analyses and these findings may imply that the same
tumor cells could also express multiple molecular profiles or
miRNAs networks. Thus, further investigation was performed
by Yang et al. (2013) to determine the miRNAs regulatory
network in mesenchymal subtypes of HGSOC, which has the
worst patients outcomes and they identified eight key miRNAs
including two members of miR-200 families which were miR-141
and miR-200a that were shown to be associated with poor
patients’ outcomes (Yang et al., 2013). However, in this study
(Yang et al., 2013), miR-506 instead of miR-200c was shown
to negatively regulate the EMT, cell proliferation, migration
and invasion of ovarian tumor cells through a direct binding
of the transcription factor, SNAI2 and subsequently suppressed
CDH1 expression. These findings show that regulation of
CDH1 expression and EMT by miR-506/SNAIL may be specific
to mesenchymal subtypes, in contrast to epithelial subtypes
of HGSOC, in which the miR-200c/ZEB may be the main
regulators. Though, further research are needed to confirm
these miRNA regulatory networks particularly that define the
molecular subtypes of HGSOC. Nevertheless, none of these
studies show any evidence of transition between the epithelial to
mesenchymal subtypes nor mesenchymal to epithelial subtypes
in HGSOC samples. Intriguingly, a study of gene expression
profiling between primary and metastatic ovarian carcinoma
revealed that despite no morphological difference between two
tumor types, there were distinguishable gene clustering profiles
that differentiate the metastatic cells from their primary cells
(Lili et al., 2013) and these identified genes were mainly involved
in EMT-related pathways. These findings may not demonstrate
the existence of EMT/MET interconversion yet, they have
shown that there are patterns of gene expressional changes
from epithelial to mesenchymal genes, despite no morphological
features are observed. Furthermore, recent study of various
ovarian cancer types showed that expression of membrane
CDH1 was almost not detected in normal ovarian epithelium,
but was higher in benign tumors, and progressively decreased in
borderline or malignant tumors and in metastatic lesions (Wu
et al., 2016). In this study (Wu et al., 2016), the expression of
VIMENTIN, a marker for mesenchymal cells, was opposite to
the CDH1 expression, thus may support the EMT/MET dynamic
interconversion during ovarian cancer progression. However,
the role of CDH1 as a tumor suppressor in ovarian cancer does
not follow the classical EMT profile (Auersperg et al., 1999;
Martin et al., 2011; Rodriguez et al., 2012), due to up-regulation
of CDH1 expression observed in tumors that were derived from
ovary (Auersperg et al., 1999), therefore more studies are needed
to clarify the role of CDH1, miR-200c and other regulatory
miRNAs, and their regulations of EMT/MET in ovarian cancer
progression.
miR-200c-Mediated Tumor Intravasation
Intravasation describes the invasion of the cancer cells into
the blood stream or lymphatic system. This mainly involves
the Notch signaling (Sonoshita et al., 2011) and TNF-α/tumor-
associated macrophages (Wyckoff et al., 2007; Zervantonakis
et al., 2012; Roh-Johnson et al., 2014). How exactly the miR-
200 family regulates intravasation is largely unknown, although
in a study on breast cancer found that both expression of miR-
200 gene clusters and overexpression of CDH1 can independently
inhibit the intravasation into the blood stream (Korpal et al.,
2011). However, limited research have been done to examine the
role of miR-200 family in cancer cell intravasation and this is
due to difficulties in measuring intravasated cells (Humphries and
Yang, 2015), therefore future work should be done in focusing on
this area.
miR-200c-Mediated Tumor Survival and
Circulation
Intravasated cells in the blood stream or lymph nodes are also
known as the circulating cancer cells (CTCs) and these CTCs
can re-program cellular processes such as apoptosis and anoikis
to enhance their survival rate (Humphries and Yang, 2015). In
the MDA-MB-231 breast cancer cell line, overexpression of miR-
200b/c/429 gene cluster as compared to miR-200a/141 caused
increased apoptosis, increased caspase activity and reduced cell
viability through phospholipase C gamma 1 (PLCG1; Uhlmann
et al., 2010). In a study on ovarian cancer, miR-200c expression
led to suppression of Fas-associated phosphatase-1 (FAP1)
and increased CD95, a death receptor, surface expression and
consequently led to increased cell sensitivity to CD95-mediated
apoptosis during CD95 agonist treatment (Schickel et al., 2010),
therefore restoring the tumor cells sensitivity toward CD95-
mediated apoptosis. Incomplete attachment of cells to ECM will
induce anoikis (Humphries and Yang, 2015), which is another
form of apoptosis, and surviving this process is one of the critical
steps in cancer cell progression. Although the mechanisms by
which the cancer cells evade anoikis are unknown, the gain
of miR-200c expression in endometrial and breast cancer in
cultures restored the sensitivity of these cells toward anoikis,
through suppression of neurotrophic-tyrosine-receptor kinase
type 2, NTRK2 (Howe et al., 2011). In this study (Howe et al.,
2011), miR-200c also suppressed the expression of fibronectin 1
(FN1), moesin (MSN), leptin receptor (LEPR) and Rho-GTPase-
activating protein 19 (ARHGAP19), and consequently inhibited
migration of these cells. A study of NTRK2 and anoikis in breast
cancer cell lines also showed that miR-200c can directly target
neurotrophin 3 (NTF3) and this NTRK2/NTF3 signaling is the
downstream effector of NFKB signaling which promotes anoikis
(Howe et al., 2012). In ovarian cancer cell lines, NTRK2 was
shown to suppress anoikis through the PIK3-AKT pathway that
resulted in more invasive and chemo-resistant cells (Yu et al.,
2008), thus suggesting the novel function of miR-200c in anoikis
besides EMT/MET cycles. In contrast, miR-200a was shown to
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promote anoikis resistance via its target, yes-associated protein
1, YAP1 (Yu et al., 2013). The functional discrepancies in miR-
200 family may be due to the single-nucleotide differences in
the seed sequence thus allowing opposite downstream actions.
However, further research is needed to elucidate the role of each
member of miR-200 in anoikis, and also their interaction with
immune system as these cancer cells managed to escape immune
surveillance to metastasize.
miR-200c-Mediated Tumor Extravasation
and Colonization
Circulating tumor cells which survived will colonize their new
niche by extravasating from circulation, induce cell proliferation
and inhabit the new area. In order for these CTCs to adhere
to endothelial cells in the new niche, they undergo MET to
facilitate the settlement by recovering their epithelial properties.
In contrast to the suppression of EMT by miR-200 family, this
metastatic colonization of cancer cells are shown to be promoted
by the miR-200 family (Drake et al., 2009; Korpal et al., 2011). In
a study using the mouse mammary tumor cell lines, loss of miR-
200b/c/429 cluster expression was observed in the 4TO7 cells
that did not colonized distant organ efficiently when compared
to the strongly metastatic 4TI cells (Dykxhoorn et al., 2009).
Importantly, when this 4TO7 cells gained miR-200c/141 gene
cluster expression and were then injected in the mice, 80% of
those mice developed lung metastases (Dykxhoorn et al., 2009).
Similarly in another study (Korpal et al., 2011), stable expression
of either gene clusters of miR-200 (miR-200a/b/429 and miR-
200c/141) in 4TO7 cells also resulted in lung and liver metastases
when these cells were injected in mice. Moreover, in this study
(Korpal et al., 2011), the miR-200c/141 gene cluster was more
potent in promoting metastasis, and this miR-200-mediated
metastases was independent of CDH1, thus suggesting other
molecular target or pathway that mediates this metastasis process.
Similar observation was also seen in a miRNAs profiling study of
human breast cancer primary tumor in comparison to metastatic
tumors (Gravgaard et al., 2012). Therefore, these studies suggest
that all members of miR-200 suppress cancer progression by
targeting the early steps in metastases cascade, however, the
miR-200c/141 gene cluster may promote the advanced stage of
metastases hence may explain the dual expression of miR-200c in
ovarian cancer (Bendoraite et al., 2010).
miR-200c POTENTIALS IN PROGNOSIS
AND EARLY DIAGNOSIS FOR OVARIAN
CANCER
Circulating miRNAs in the Blood
Many studies have shown that miRNAs exist in the circulating
blood which represents the environment of tissues or organs.
MicroRNAs have also been shown to be released into the blood
and are internalized into adjacent target cells (Chen et al.,
2015). Circulating miRNAs are stable even in harsh conditions
such as boiling and repetitive freeze-thaw cycles due to their
association with proteins (Mitchell et al., 2008; Arroyo et al.,
2011; Cortez et al., 2012), thus making miRNAs as the most
suitable candidate for ovarian cancer early diagnostic screening.
A study of sera collected from 28 serous EOC patients and
compared to 28 healthy normal controls (Kan et al., 2012),
showed elevated expression of miR-200a, miR-200b, and miR-
200c in cancer patients with miR-200c expression being most
significantly altered. Another study using sera collected from
70 EOC patients and compared to 70 age-matched healthy
controls revealed elevated expression of miR-200c in all advanced
stage EOC patients, and in all 18 EOC patients with confirmed
metastases (Zuberi et al., 2015). These findings showed the
possibility of using miR-200c as a diagnostic tool for ovarian
cancer through the fluid biopsy approach. It is still necessary
to investigate the role of miR-200c in the prognosis of ovarian
cancer in a much larger cohort to evaluate the specificity of the
miRNAs action in different EOC stages and subtypes.
Circulating Exosomal miRNAs
Another source of circulating miRNAs is from exosomes, which
are small membrane vesicles (30–100 nm in size) that are secreted
by different cells types such as dendritic cells, lymphocytes
and also tumor cells by exocytosis (Srivastava et al., 2015;
Yu et al., 2015). Exosomes exist in almost all body fluids
including plasma, breast milk, and saliva (Lässer et al., 2011;
Yu et al., 2015) and commonly contains proteins, lipids, and
nucleic acids such as miRNAs. The packaging of miRNAs in
exosomes is selective and usually depends on their cell origin
(Pant et al., 2012; Schwarzenbach, 2015). Exosomes are involved
in cell-to-cell communication by transferring proteins, lipids,
and nucleic acids that may also result in the change of wild
type cells to malignant cells (Ratajczak et al., 2006; Valadi
et al., 2007; Chen et al., 2012). In a study on ovarian cancer,
miRNAs of tumor-derived exosomes were isolated from 50
serous ovarian carcinoma patients’ sera (110). Interestingly, the
list of differentially expressed miRNAs is similar to another
study performed on tissues (Iorio et al., 2007), suggesting that
isolated miRNAs of tumor-derived exosomes may sufficiently
reflects the expressional miRNAs profiles of tumor tissues. In this
exosome study (Taylor and Gercel-Taylor, 2008), the expression
of eight miRNAs (miR-21, miR-141, miR-200a, miR-200b, miR-
200c, miR-203, miR-205, and miR-214) were upregulated while
none of these circulating miRNAs were detected in the normal
healthy samples. Notably, miR-200c and miR-214 expression
were reduced in stage I patients in comparison to stage II and III
patients, though across all samples, their expression were higher
in all malignant groups when compared to benign and healthy
groups (Taylor and Gercel-Taylor, 2008), which may indicate
the variability of miRNAs expression derived from exosomes as
well as due to the tumor stage and progression. A more recent
study involving 163 EOC patients revealed a similar finding of
elevated miR-200 family in ovarian cancer patients compared to
normal samples (Meng et al., 2016). The study also found that
miR-200c and 200b were associated with lymph node metastasis,
FIGO stage III-IV and poor survival outcomes, while miR-
200a was implicated with all stages. These differential elevated
miRNAs may be due to disease progression especially in different
histological subtypes between the EOC samples, or may also be
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due to selective packing of exosomes in which the exosomes
respond to different types of miRNAs to facilitate the changes.
Nevertheless, these newly identified miRNAs in exosomes may
become a new non-surgical diagnostic target for early screening
purposes.
Circulating miR-200c Potential in Early
Diagnosis
A recent systemic review reported the potential role of miR-
200c as a biomarker for diagnosis in ovarian cancer (Shao et al.,
2015). No relationship was found between miR-200c expression
in the tissue samples with the patients’ outcomes (12 out 18
studies), however, when the tissue samples were categorized
into the histological subtypes and cancer stages (four out of
12 studies), low expression of miR-200c in the primary tissue
was negatively correlated with poor outcome but only in stage
I patients (Shao et al., 2015). Since miR-200c suppresses EMT
through suppression of ZEB1/2, early stage tumors with reduced
miR-200c expression may gain migratory and invasive properties
following EMT resulting in a greater chance for metastases,
leading to poor prognosis of patients. Only six studies analyzed
the serum/blood miR-200c levels in cancer patients (Shao et al.,
2015), and five out of these six studies showed that high levels
of miR-200c in the sera correlated with the worst outcomes
in the patients irrespective of the cancer stages. Three studies
involving patients with advanced stage ovarian also revealed the
similar relationship between miR-200c expression and survival
outcomes (Shao et al., 2015). The increase of miR-200c in the
advanced stages may suggest MET in the cancer cells to drive the
settlement in the new niche. Similarly, in studies on colorectal
and breast cancers, miR-200c expression in the sera correlated
positively with metastatic tissues, but not with primary tumor
tissues (Hur et al., 2013; Toiyama et al., 2014; Madhavan et al.,
2016), indicating the dynamic change of miR-200c expression at
different points of cancer progression. This specificity of miR-
200c expression pattern between tissue and blood samples may
offer the potential of miR-200c as a biomarker in ovarian cancer
to distinguish between early and advanced tumors. There is
a need for larger studies to assess the functional outcomes of
miR-200c in ovarian cancer patients, as well as determining the
differences among the subtypes in terms of cancer progression
for developing effective intervention and improving survival
outcomes.
miR-200c Dual Expression Profile in
Ovarian Cancer Treatment
miR-200c has a prominent role in the regulation of EMT/MET
transition and its expression levels in EOC patients are influenced
by the subtypes and grades of the cancer (Bendoraite et al.,
2010). One of the key issues with the treatment of ovarian
cancer is the high incidence of relapse, which is mediated by
the presence of chemotherapy resistance. One of the mechanisms
that contributes to chemotherapy resistance in ovarian cancer is
through TUBB3, a class III β-Tubulin (Umezu et al., 2008; Aoki
et al., 2009; Roque et al., 2013). miR-200c has been shown to
directly target TUBB3 mRNA and repress its expression, thus
increasing the chemo-sensitivity to drugs such as paclitaxel and
docetaxel (Cochrane et al., 2010; Howe et al., 2011; Chang et al.,
2015). Subsequently, low expression of miR-200c is implicated in
poor patients’ outcome and paclitaxel resistance in ovarian cancer
(Leskelä et al., 2011; Marchini et al., 2011). The overexpression of
miR-200c led to suppression of TUBB3 and restored the paclitaxel
sensitivity in chemotherapy-resistant cancer cell lines (Cochrane
et al., 2009, 2010; Cittelly et al., 2012) and in a xenograft tumor
model (Cittelly et al., 2012), suggesting the positive role of miR-
200-c as therapeutic agents in ovarian cancer treatment. There
is a study which showed that a high expression of miR-200c
was also associated with poor prognosis in serous ovarian cancer
(Nam et al., 2008), while another showed no association between
miR-200c expression and the patients’ outcome (Hiroki et al.,
2010). These differences in outcomes linked to the role of miR-
200c in chemotherapy may illustrate the underlying mechanisms
in the miR-200c regulation of TUBB3. This theory is supported
by the presence of the RNA binding protein Hu-antigen R
(ELAVL1), which stabilizes TUBB3 and promotes its abundance
(Raspaglio et al., 2010), and can cooperate with miRNAs to
repress mRNA expression (Wang et al., 2013; Kotta-Loizou et al.,
2014). Depending on the location of the ELAVL1 in the cells, miR-
200c exerts differential actions on TUBB3 expression. When the
localization of ELAVL1 is predominantly in the nucleus, miR-
200c represses expression of TUBB3 leading to sensitivity to
chemotherapy, while cytoplasmic ELAVL1 interacts with miR-
200c to enhance expression of TUBB3 and causes chemotherapy
resistance and poor outcomes (Prislei et al., 2013). These
differential associations between TUBB3, ELAVL1, and miR-
200c may clarify the differences in the chemotherapy treatment
outcomes particularly in the action of miR-200c in ovarian
cancer. Other studies also have shown that cytoplasmic ELAVL1
expression correlated with poor survival outcomes (Erkinheimo
et al., 2003; Denkert et al., 2004) and the nuclear ELAVL1
expression correlated with better outcomes in the patients (Yi
et al., 2009). Nevertheless, a recent study done to determine
prognostic role of ELAVL1 in ovarian cancer found no significant
role of ELAVL1 localization in determining the patient outcomes
as well as its interaction with miR-200c (Davidson et al., 2016).
These inconsistencies in the findings may due to the technical
aspects of those studies, such as the various stages of the EOC
progression, in which the recent study only analyzed the late
stages of serous EOC as compared to the others which involved
a wider range of samples. Moreover, the prognostic roles of
miR-200c and TUBB3 in restoring chemotherapy sensitivity in
ovarian cancer is possibly a cell-context dependent (Brozovic
et al., 2015). Therefore, further research are needed especially in
animal models to standardize the stages of cancer progression
as well the sites of the samples taken in order to determine
the complexity and interaction of ELAVL1 and miR-200c in
regulating TUBB3 expression and contribution to chemotherapy
resistance and patient outcomes in ovarian cancer.
In terms of platinum-based chemotherapy drugs such as
cisplatin, oxaliplatin, and carboplatin, the main mechanism for
these drugs is to damage the DNA and thus induces genetic
instability within the tumor cells. Previous studies have shown
that the platinum-based drug resistance in ovarian cancer
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treatment primarily due to the sequestering of the drugs in
the sub-cellular compartments in the cells via ATP-dependent
Cu+ transporting P-type 7A or 7B (ATP7A/ATP7B) (Samimi
et al., 2004; Yoshizawa et al., 2007; Kalayda et al., 2008; Safaei
et al., 2012, 2013; Harrach and Ciarimboli, 2015) or due to
ATP7A/ATP7B chaperone protein, ATOX1 (Safaei et al., 2009).
Recent study has shown that other transporters such as LRRC8A,
cation transporter (Sørensen et al., 2016) can also contribute
to the cisplatin resistance. Nevertheless, until now, there is
no available research that has shown the validated relationship
between the platinum-based drug resistance and miR-200c
expression and their consequences in the ovarian cancer patient
survival, nor any of the research directly shows the molecular
targets of miR-200c being implicated in the resistance in ovarian
cancer. However, in a study in esophageal cancer, an expression
of a subunit phosphatase 2A (PPP2R1B) that negatively regulates
AKT phosphorylation was increased following knockdown of
miR-200c and this protein was implicated in the resistance
to cisplatin (Hamano et al., 2011). In a study of melanoma
(Liu et al., 2012), a knockdown of a polycomb group protein
(BMI1) expression in these tumor cells resulted in higher chemo
sensitivity of these cells toward cisplatin together with a presence
of reduced ATP-binding-cassette (ABC) transporters, which are
the transporters of various substance in the cells. BMI1 is
a validated target of miR-200c (Cui et al., 2014), thus this
suppression of BMI1 by miR-200c may therefore also suppresses
ABC transporters levels and promotes the cisplatin sensitivity in
ovarian cancer, however, further research is needed to address
this relationship and how will it affects the survival outcomes
of the ovarian cancer patients. Nevertheless, the majority of the
findings showed the potential of miR-200c as a biomarker for
early screening and the possible therapeutic approach for women
with ovarian cancer has more credibility and potential than its
chemo-resistance role.
CONCLUSION
The lack of early screening strategy in ovarian cancer as well as
the incidence of chemo-resistance and relapse during treatment
contribute to the high mortality rate of this disease. Extensive
studies have been done to identify the factors regulating the
metastasis cascade in cancer progression. MiRNAs have been
shown as potential regulators, with possible value as a biomarker
and also as a therapeutic agent, particularly the miR-200c. Despite
the reported issue of chemo-resistance with elevated expression
of miR-200c in ovarian cancer patients, it seemed that miR-200c
provides more beneficial outcomes as a biomarker and possibly
as therapeutic agents due to its functional regulation of EMT
and metastasis. Future research should be done to determine
the role of individual miR-200 family members in regulating the
metastasis and cancer progression, especially in a large cohort to
further clarify the molecular network and pathway of miR-200c
regulation. There is also a need to investigate the validated targets
of miR-200c in animal models to differentiate their function
between EOC subtypes and grades as well as their impact on
survival outcomes.
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